Year All202320222021 9/14/2023 Neumora Therapeutics Announces Pricing of Initial Public Offering Read More 7/18/2023 Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder Read More 7/18/2023 Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer Read More
7/18/2023 Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder Read More
7/18/2023 Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer Read More
